PCMA has expressed its concern over the lobbying. “This campaign undermines e-prescribing’s two main goals: improving patient safety and reducing prescription drug costs. Doctors should be able to check for dangerous drug-drug interactions and help patients find affordable options,” said PCMA President and CEO Mark Merritt.
According to the news release, the drug manufacturers are pushing to prohibit physicians from seeing all lower cost options, such as cheaper generics and preferred brands; prevent the technology from showing safety information, such as drug-drug interactions; and disallow any choice of lower-cost pharmacy options.
The legislation is pending in 11 states, including Indiana, Kansas, Mississippi, Missouri, Nebraska, New Mexico, New Jersey, North Dakota, Oklahoma, Pennsylvania and South Dakota.
Read the news release about e-prescribing.
Read other coverage about e-prescribing:
– Interoperability at the Forefront of ONC’s 2011 Agenda
– CMS Makes Minor Revisions to Meaningful Use Final Rule
– AMA, Other Medical Societies Urge HHS to Revise e-Prescribing Penalty Policy
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
